Last reviewed · How we verify
GSK1034702
At a glance
| Generic name | GSK1034702 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects (PHASE1)
- Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702 (PHASE1)
- Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study (PHASE1)
- A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1034702 CI brief — competitive landscape report
- GSK1034702 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI